Meeting
2022 ASCO Annual Meeting
Trabectedin in advanced retroperitoneal well differentiated/dedifferentiated liposarcoma and leiomyosarcoma (TRAVELL): Results of a phase 2 study from Italian sarcoma group (ISG).
Authors
Roberta Sanfilippo
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Roberta Sanfilippo , Giovanni Grignani , Chiara Fabbroni , Bruno Vincenzi , Elena Fumagalli , Tommaso Martino De Pas , Alessandro Mazzocca Jr., Toni Ibrahim , Maria A. Pantaleo , Antonella Brunello , Giacomo Giulio Baldi , Antonella Boglione , Sonia Fatigoni , Andrea Marrari , Alfredo Berruti , Monica Giordano , Angelo Paolo Dei Tos , Luciano Carlucci , Eliana Rulli , Paolo Giovanni Casali
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
2012-005428-14
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11575)
DOI
10.1200/JCO.2022.40.16_suppl.11575
Abstract #
11575
Poster Bd #
479
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2017 ASCO Annual Meeting
Trabectedin for advanced soft tissue sarcoma: Ten-year real-life perspective.
First Author: Sivan Shamai
Poster
2014 ASCO Annual Meeting
Phase II study of eribulin mesylate in patients (pts) with advanced soft tissue sarcoma (STS).
First Author: Yoichi Naito
Poster
2012 ASCO Annual Meeting
Growth modulation index and RECIST-based STBSG-EORTC criteria for the assessment of drug activity in advanced soft tissue sarcoma (ASTS) patients (pts).
First Author: Sophie Cousin